Given the surging popularity of obesity management drugs in recent years, the FDA put out a warning singling out compounded GLP-1s, calling them risky for patients. The agency said it had received hundreds of reports of adverse events linked to compounded semaglutide (392) and tirzepatide (215) as of Nov
Liu X, Zhang Y, Zheng SY, Lin R, Xie YJ, Chen H, Zheng YX, Liu E, Chen L, Yan JH, Xu W, Mai TT, Gong Y
Wright, however, was quick to shut them down, warning of the aftereffects and the judgmental looks from others
Pharmacological modulation of nitric oxide release: new pharmacological perspectives, potential benefits and risks
Lemme's website says that the product will "Support GLP-1: Promote your body's GLP-1 production (the 'un-hunger' hormone), reduce hunger & cravings, promote fat reduction and support healthy weight management with 3 clinically-studied ingredients." Glucagon-Like Peptide-1 (GLP-1) is a natural hormone in the body that is released in the gut after eating and acts to suppress appetite